COMPANY SHOWCASE

AxioBiosolutions (www.axiobio.com) is a medtech company focused on novel biomaterial-based devices for management of trauma, surgical and chronic wounds. Its flagship product, Axiostat is an FDA 510k cleared, CE approved hemostat made of 100% chitosan that controls moderate to severe bleeding within minutes. Headquartered in Cambridge MA, Axio has its corporate office in Bangalore and FDA, GMP-certified manufacturing facility in Ahmedabad, India. The company has built a strong R&D portfolio, with multiple global patents to its credit in the wound healing, mucoadhesive drug delivery and the hemostat space. Axio counts Accel, University of California and Ratan Tata's UC-RNT and Chiratae ventures as its investors.

Activities / Partnering avenues:
- Launching hemostatic range in the US soon
- Mucoadhesive platform based on 100% chitosan
- 12+ indications cleared in Surgical, Trauma, Military, Dental and Hemodialysis segments
- Latest launch :Maxiocel, a 100% chitosan microfiber dressing for non healing chronic wounds

Biofi’s vision is to make monitoring of vital health parameters EASY, PAIN FREE, AFFORDABLE & provide intelligent, personalized information to individuals through NON INVASIVE measurement of important biomarkers/body parameters. Non-Invasive Blood glucometer, disposable ECG patch (with Heart Rate Variability Analytics), Cuffless Blood Pressure meter, Neonatal Scope, VitaminD enhancers are some of the products Biofi is focusing to bring to the market over the next three years. A leadership team with 8 patents and over 100 man years of industry experience, guided by eminent doctors and technical advisors, seed funded by veteran VCs and winner of 3 Startup awards, team Biofi is looking to make a difference.

K&S Partners is an Intellectual Property (IP) Law Boutique

• Established in 1994
• Vision is to be ‘the finest IP Law Firm in India’
• Unique and professional ownership structure
• A well-organised Portfolio-based service delivery mechanism
• Client focused teams led by Partners
• Practice coordinator led practice areas in Patents
• Seamless collaboration with distinct emphasis on quality, ethics and promptness
• State of the art infrastructure includes
  - Document Management System (DMS) - digitalizes all documents and helps maintain a paperless office
  - ERP Application - maintains databases, processes, billing and time records
  - Proprietary databases for Patents and Trademarks
  
• Ranked as Tier 1 in the Patent Prosecution by Managing Intellectual Property (MIP) 2019
• Ranked amongst top PCT filers in India by MIP for last several years

Mapmygenome is a leading consumer genomics company that leverages state of art DNA sequencing technologies and the latest research to prevent and diagnose complex genetic disorders. Established in 2013, Mapmygenome is led and funded by some of the most successful entrepreneurs and investors like Mr Ratan Tata and Rajan Anandan. Stemmed from Ocimum Biosolutions, Mapmygenome is backed by 19+ years of experience in genomics. Mapmygenome offers personalized health, fitness and wellness solutions based on genetic tests that help people lead healthier lives. Some of the top-selling products include GenomepatriTM and NGS based advanced molecular diagnostics.

Stempeutics Research Bangalore is a late stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells. Company’s flagship product - Stempeucel® is a Phase III ready, allogeneic, cultured, pooled, off-the-shelf, bone marrow derived mesenchymal stromal cell (“MSC”) product. Stempeucel® is being developed for the treatment of Critical Limb Ischemia due to Buerger’s disease (amongst other indications such as osteoarthritis and diabetic foot ulcer). Stempeucel® is the FIRST innovative stem cell based biological product to be approved by DCGI (Indian FDA) for limited sales for the treatment of Critical Limb Ischemia due to Buerger’s disease. Currently Phase 4/PMS study is in progress in India. Stempeutics is seeking partners for further clinical development and commercialization of Stempeucel® in US/Europe/Japan.

VNIR Biotechnologies Pvt Ltd is a startup innovating molecular probes for live cell imaging and detection of various cellular and disease markers. A spin-off from one of the top research Universities in India, VNIR is proud to introduce a VNIR ADs for Alzheimer’s detection. As a small molecule that can cross blood brain barrier, and detect Alzheimer’s specifically without any confusing signals from other neurodegenerative diseases or mixed dementia opens the opportunity for performing IR/PET scans in mouse-models and in clinical studies. We are endeavoring to enter the next frontier in Alzheimer’s diagnostics with these molecular probes.

Profile

• We are on a mission to develop novel immuno oncotherapeutics that drive transformational improvements in cancer treatment through NK cell engagement
• We leverage proven proprietary antibody discovery- INABLR™ for fast track Antibody discovery and development
• Our team works in collaboration with a world class Scientific Advisory Board with expertise in immuno-oncology and clinical development
• Our lead asset (ZM008) is a first-in-class antibody that targets certain receptors that blocks NK cell inhibitory signal and enables NK cell activation to generate a potent immune response. Development is on track for an IND filing by Q4 2020 and Phase 1 clinical trial in Q1 2021

Partnerships

• Global partnership for antibody discovery services with Syngene International
• Collaborative project with Prof. Vijay Kuchroo Laboratory (Harvard Med School) for discovery of unique human monoclonal antibodies against a novel cytokine

We are actively seeking early stage licensing and co-development opportunities for our lead asset and antibody discovery platforms

Investment & Funding

• Capital raised from inception: 20Mil$
• Looking to raise: 25Mil$ in Series A2
• Current investors include Accel in the lead